Invited Commentary: The specialty of adult congenital heart disease

about

Invited Commentary: The specialty of adult congenital heart disease

Item

http://www.wikidata.org/entity/Q38980748

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Invited Commentary: The specialty of adult congenital heart disease

@en

type

Item

label

Invited Commentary: The specialty of adult congenital heart disease

@en

prefLabel

Invited Commentary: The specialty of adult congenital heart disease

@en

P1476

Invited Commentary: The specialty of adult congenital heart disease

@en

P2093

Ari M Cedars

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Managemen

Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption

Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.

Trends in hospitalizations for adults with congenital heart disease in the U.S.

Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality.

Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010.

Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study.

Specialized adult congenital heart disease care: the impact of policy on mortality.

Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.

A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot.

P304

174-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/08998280.2016.11929405

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27034559

http://www.w3.org/2001/XMLSchema#string

P921

birth defect

P932

4790561

http://www.w3.org/2001/XMLSchema#string